
Strength Training Can Improve Lymphedema in Breast Cancer
A recent study found that 3 months of resistance training did not worsen lymphedema in breast cancer survivors and instead significantly improved fluid balance and increased upper extremity muscle mass. The edema index also improved, suggesting potential therapeutic benefits of intense resistance training for managing lymphedema.
METHODOLOGY:
Lymphedema is a common adverse effect of breast cancer treatment that can limit mobility. Although strength training can have multiple benefits for breast cancer survivors, such as increased bone density and metabolism, data on whether more intense resistance training exacerbates lymphedema in this population are limited. Worries that more intense training will lead to or worsen lymphedema have typically led to cautious recommendations.
Researchers conducted a cohort study involving 115 women with breast cancer (median age, 54 years; 96% White; 4% Black) between September 2022 and March 2024. Most (83%) underwent sentinel lymph node biopsy (SLNB), while 12% had axillary lymph node dissection (ALND). At baseline, 13% had clinical lymphedema, including 37% in the ALND group and 8% in the SLNB group.
Participants attended resistance training sessions three times a week, with intensity escalation over 3 months. Exercises involved hand weights, resistance bands, and body weight (eg, pushups) to promote strength, mobility, and muscle hypertrophy.
Bioimpedance analysis measured intracellular water, extracellular water, and total body water before and after exercise. Lymphedema was defined as more than a 3% increase in arm circumference discrepancy relative to preoperative ipsilateral arm measurements, along with an elevated edema index (extracellular water to total body water ratio).
TAKEAWAY:
No participants experienced subjective or clinical worsening of lymphedema after completing the resistance training regimen.
Lean mass in the affected arm increased from a median of 5.45 lb to 5.64 lb (P < .001), while lean mass in the unaffected arm rose from 5.51 lb to 5.53 lb (P < .001) after the resistance training.
Overall, participants' fluid balance improved. The edema index in both arms showed a significant reduction at training completion (mean, 0.383) vs baseline (mean, 0.385), indicating reduced lymphedema. Subgroup analysis of women who underwent SLNB showed similar improvements in the edema index.
IN PRACTICE:
'These findings highlight the safety of strength and resistance training in a large group of patients with breast cancer during and after treatment,' the authors wrote. Beyond that, the authors noted, the results point to a potential role for resistance training in reducing lymphedema.
SOURCE:
This study, led by Parisa Shamsesfandabadi, MD, Allegheny Health Network, Pittsburgh, was published online in JAMA Network Open.
LIMITATIONS:
A major limitation was the absence of a control group, which prevented a direct comparison between the effects of exercise and the natural progression of lymphedema. The 3-month intervention provided limited insight into the long-term sustainability of benefits. Patient-reported outcomes were not included. Additionally, potential confounding variables such as diet, medication use, and baseline physical activity levels were not controlled for in the analysis.
DISCLOSURES:
The authors did not disclose any funding information. Several authors reported having ties with various sources. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Meta names ChatGPT co-creator as chief scientist of Superintelligence Lab
By Echo Wang NEW YORK (Reuters) -Meta Platforms has appointed Shengjia Zhao, co-creator of ChatGPT, as chief scientist of its Superintelligence Lab, CEO Mark Zuckerberg said on Friday, as the company accelerates its push into advanced AI. "In this role, Shengjia will set the research agenda and scientific direction for our new lab working directly with me and Alex," Zuckerberg wrote in a Threads post, referring to Meta's Chief AI Officer Alexandr Wang, who Zuckerberg hired from startup Scale AI when Meta took a big stake in it. Zhao, a former research scientist at OpenAI, co-created ChatGPT, GPT-4 and several of OpenAI's mini models, including 4.1 and o3. He is among several researchers who have moved from OpenAI to Meta in recent weeks, part of a broader talent arms race as Zuckerberg aggressively hires from rivals to close the gap in advanced AI. Meta has been offering some of Silicon Valley's most lucrative pay packages and striking startup deals to attract top researchers, a strategy that follows the underwhelming performance of its Llama 4 model. Meta launched the Superintelligence Lab recently to consolidate work on its Llama models and long‑term artificial general intelligence ambitions. Zhao is a co-founder of the lab, according to the Threads post, which operates separately from FAIR, Meta's established AI research division led by deep learning pioneer Yann LeCun. Zuckerberg has said Meta aims to build 'full general intelligence' and release its work as open source — a strategy that has drawn both praise and concern within the AI community.
Yahoo
4 minutes ago
- Yahoo
ChristianaCare opens neighborhood hospital in Chester County, Pennsylvania
ChristianaCare is opening its first neighborhood hospital in the company's 188-year history over the Delaware line northwest of Hockessin in Chester County, Pennsylvania. ChristianaCare Hospital, West Grove, is scheduled to open in mid-August at 1015 W. Baltimore Pike, West Grove, offering a new model of emergency and acute care in a modern, easy-to-access setting. The 20,000-square-foot hospital will be open 24 hours a day, seven days a week. Developed in partnership with Emerus Holdings Inc., the nation's leading developer of neighborhood hospitals, this facility will be staffed with board-certified emergency physicians, skilled nurses and clinical specialists. 'It's an honor and privilege to expand access to high-quality care for our neighbors in southern Chester County,' said Janice Nevin, president and CEO of ChristianaCare, in a press release. 'We will be opening our doors for the families in this community with a steadfast commitment to being their trusted health care partner. We're grateful for the opportunity to bring love and excellence to those we will serve.' Nevin said the project has received strong local support and was made possible in part by generous grants from the Commonwealth of Pennsylvania and the Chester County Board of Commissioners – Josh Maxwell, Marian Moskowitz and Eric Roe – whose leadership helped bring this vision to life. ChristianaCare Hospital, West Grove, is designed to meet a wide range of everyday medical needs with: A full-service emergency department with 10 treatment rooms. A 10-bed inpatient unit for overnight stays, observation and diagnostics. Advanced imaging and lab services, including ultrasound, CT scan and X-ray. Virtual access to specialists in such areas as cardiology, critical care and infectious disease. The emergency department is equipped to treat conditions such as falls, injuries, heart attacks and strokes. Patients requiring surgery or more complex care will be stabilized and transferred to a hospital with more expanded service offerings based on the clinical needs of the patient. 'This neighborhood hospital brings the right mix of services to support the health and well-being of our neighbors,' said Pauline Corso, president of ambulatory network continuity and growth at ChristianaCare. 'We're excited to bring care close to home to meet the needs of the community. We're here to stay and grow alongside this community.' As part of its long-term investment in the West Grove Campus, ChristianaCare has also purchased the building at 900 W. Baltimore Pike, across the street from the hospital. This facility houses a ChristianaCare primary care practice and imaging services, offering walk-in X-rays and scheduled mammography and ultrasound appointments. This health center will continue to evolve to meet the growing needs of the community, Nevin said. More hospital news: What Medicaid, Medicare cuts could mean for Delaware's hospitals, especially in rural areas More expansion plans in southeastern Pennsylvania ChristianaCare is expanding its neighborhood hospital model to address care gaps across southeastern Pennsylvania, Nevin said. New hospitals are being planned for Aston and Springfield Townships in Delaware County, with the Aston location under construction and expected to open in late 2026. In addition, ChristianaCare was the successful bidder for Crozer Health outpatient centers in Glen Mills, Havertown, Broomall and Media, further strengthening its regional footprint and ability to deliver timely, high-quality care. More on Crozer Health ChristianaCare to take on 5 Crozer Health outpatient locations with $50M bid History of care in southeastern Pennsylvania and Delaware ChristianaCare's presence in southeastern Pennsylvania is long-standing. The organization provides primary care at three Chester County locations – Kennett Square, Jennersville and West Grove – and recently opened a cardiology practice in West Grove. In neighboring Delaware County, the Concord Health Center in Chadds Ford offers a wide range of services, including primary care, women's health, sports medicine and behavioral health. Together, these sites serve as the medical home for more than 25,000 residents, underscoring ChristianaCare's deep commitment to delivering accessible, high-quality care where it's needed most, Nevin said. Headquartered in Wilmington, Delaware, ChristianaCare also has a network of primary care and outpatient services, home health care, urgent care centers, four hospitals with a total of 1,440 beds, a freestanding emergency department, a level-one trauma center and a level-three neonatal intensive care unit, a comprehensive stroke center, the Gene Editing Institute and regional centers of excellence in heart and vascular care, cancer care and women's health. Reporter Ben Mace covers real estate, development and business news. Reach him at rmace@ This article originally appeared on Delaware News Journal: ChristianaCare opens neighborhood hospital in southeastern Pennsylvania Solve the daily Crossword